Keywords: USA, Pay-to-delay, GPhA, FTC, Patent settlements

US generic group GPhA slams FTC position on patent settlements as “misguided”

Article | 29 July 2010

• Print This

Commenting on US Federal Trade Commission Chairman Jon Leibowitz’ testimony before the House of Representatives Committee on the Judiciary, Subcommittee on Courts and Competition Policy (The Pharma Letter July 28), the Generic Pharmaceutical Association (GPhA) described it as misguided and failing to present the whole story regarding patent settlements.

The six months of data presented by the FTC does not override the fact that over the past 10 years patent settlements – often described as “pay-to-delay” deals - have enabled dozens of first-time generics to come to market many months before patents on the counterpart brand drugs expired. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.